Clinical trials: Healthy Smokers
- Condition Healthy Smokers
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Tobacco Use Disorder
A Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Healthy Adult Smokers
This is a randomized, open-label, single-dose, three-period, crossover, single-center comparative bioavailability (BA) study under fasting condition in Chinese healthy male adult participants with a history of cigarette smoking.
- Trial name
- NCT02688374
- Testing
- Treatment A: Nicorette 2 mg coated mint gum, Treatment B: Nicotinell 2 mg coated mint gum, Treatment C: Nicotinell 2 mg coated fruit flavor gum
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tobacco Use Disorder, Smoking
A Pilot Study to Evaluate the Efficacy of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge
This is a study to determine the safety and effectiveness of silver salt in Ariva® Silver Wintergreen Lozenge on discouraging smoking, by its imparting an unfavorable taste to the smoker when tobacco is smoked.
- Trial name
- NCT01336816
- Testing
- Ariva Silver Wintergreen
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Star Scientific, Inc
Smoking
A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers
The purpose of this study is to assess the comparability of the phase 3 lot and a single commercial lot of NicVAX in healthy smokers.
- Trial name
- NCT01375933
- Testing
- NicVAX Vaccine
- Where
- 6 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Nabi Biopharmaceuticals
Thromboangiitis Obliterans (Buerger's Disease)
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
This study is a first-in-human clinical trial of drug ATI-1013, in healthy adult cigarette smokers. The main questions it aims to answer are to learn about the safety of drug ATI-1013, how long drug ATI-1013 remains within the…
- Trial name
- NCT07215923
- Testing
- ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Antidote Therapeutics, Inc
Healthy, Healthy Smoker
Inhaled RB042 in Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease
This is a 4-part, randomised, double-blind, placebo-controlled, first in human study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of inhaled RB042.
- Conditions
- Healthy, Healthy Smoker, COPD (Chronic Obstructive Pulmonary Disease), COPD
- Trial name
- NCT07285122
- Testing
- RB042
- Where
- Australia
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Atisama Therapeutics
Smoking, Tobacco Smoking
Reduced Exposure to HPHC in Smokers Switching From Cigarettes to Different Versions of THS
This was a randomized, controlled, open-label, 4 parallel arm study with a stratified randomization by sex (a quota for each sex [females and males] of at least 40% overall).
- Conditions
- Smoking, Tobacco Smoking, Tobacco Use
- Trial name
- NCT05599451
- Testing
- THS Blade device, THS Induction Mono device, THS Induction Mid device
- Where
- United Kingdom
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Mental Disorders
A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers
This will be a double blind, randomised, placebo controlled, cross over study in which up to 20 otherwise healthy male nicotine abstinent smokers will be tested following 3 acute treatment conditions (placebo, 4 and 8mg of…
- Trial name
- MAA113746 (NCT01371799)
- Testing
- Drug
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Smoking
Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L
The purpose of this study is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD, i.e., subjective effects) profiles, and the safety and tolerability of the nicotine-containing aerosol delivered by Platform 3 Liquid…
- Trial name
- NCT02532374
- Testing
- Nicorette® inhalator, P3L
- Where
- New Zealand
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking, Healthy
Determination of Biomarkers of Exposure and Biomarkers of Potential Harm in Asian Adult Cigarette Smokers
The purpose of this study is to determine biomarkers of exposure to Harmful and Potentially Harmful Constituents (HPHCs) in Cigarette Smoke and cardiovascular-related biomarkers in smokers and non smokers.
- Trial name
- NCT02103751
- Where
- Japan
- Volunteers
- 1,069 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking Cessation
Single-Dose Bioequivalence Study Comparing Two 4 mg Nicotine Lozenges
The purpose of the study is to compare the pharmacokinetic (PK) profiles and assess bioequivalence between a new nicotine lozenge and a reference nicotine lozenge in healthy smokers
- Trial name
- NCT03432312
- Testing
- Nicotine lozenge
- Where
- South Africa
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Fertin Pharma A/S
Substance Dependence
A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers
Study to investigate the safety, tolerability and pharmacokinetics of GSK598809 in otherwise healthy volunteers. This study is required because this drug is being developed for the treatment of nicotine dependence.
- Trial name
- NCT00728052
- Testing
- GSK598809
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Smoking Abstinence
Effects of AFQ056 and Nicotine in Reducing Cigarette Smoking
The purpose of this study is to assess the safety and efficacy of AFQ056 and nicotine compared to placebo on craving and withdrawal symptoms during voluntary smoking stoppage in healthy smokers.
- Trial name
- NCT00414752
- Testing
- AFQ065
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novartis
Smoking Cessation
Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers
The primary objective of this trial is to assess the effects of cytisinicline at therapeutic and supratherapeutic doses on cardiac repolarization relative to placebo in healthy adult subjects who are smokers.
- Trial name
- NCT05566288
- Testing
- Cytisinicline, Moxifloxacin
- Where
- Portugal
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Achieve Life Sciences
Smoking
Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting
Evaluate if the ad libitum use of the THS 2.2 Menthol (mTHS), a candidate Modified Risk Tobacco Product, for 5 days in confinement, and after 86 days in an ambulatory setting, by apparently adult healthy smokers results in a…
- Trial name
- NCT01989156
- Testing
- THS 2.2 Menthol (mTHS 2.2), Menthol Conventional Cigarette (mCC), Smoking Abstinence (SA)
- Where
- 2 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking
Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.
The overall goal of the study is to evaluate if the ad libitum use of the Tobacco Heating System 2.2 (THS 2.2) for 5 days by adult healthy smokers results in a reduction in the levels of biomarkers of exposure (BoExp) for…
- Trial name
- NCT01959932
- Testing
- Tobacco Heating System (THS 2.2), Smoking abstinence (SA), Conventional cigarette (CC)
- Where
- Poland
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Cigarette Smoking
Nicotine Pharmacokinetics From Research Electronic Nicotine Delivery System S-TA-U001 in Smokers and E-Cigarette Users
To better understand the PK and associated pharmacodynamic (PD) responses produced by the Research ENDS S-TA-U001 product, this study will compare the Research ENDS S-TA-U001 to The subject's own brand combustion (non-menthol)…
- Trial name
- NCT02792426
- Testing
- Research ENDS S-TA-U001, Nicorette Inhalator
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- NJOY, Inc.
Nicotine, Vaping
Reduced HPHC Exposure in Cigarette Smokers Switching to P4M3 Gen. 2.0 Compared to Continuing Smoking, or Smoking Abstinence
To demonstrate the reduction of Biomarkers of Exposure (BoExp) to selected harmful and potentially harmful constituents (HPHC) in smokers switching from cigarette (CIG) to P4M3, an Electronic Nicotine Delivery System (ENDS)…
- Conditions
- Nicotine, Vaping, Nicotine Vaping
- Trial name
- NCT05487456
- Testing
- P4M3 CA35, P4M3 CM35, CIG
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Healthy Volunteers
A Study to Assess Tobacco-related Biomarkers of Exposure in Smokers Using myBlu E-cigarettes
The purpose of this study is to assess changes in exposure to selected harmful and potentially harmful substances related to tobacco/nicotine use when adult smokers switch from their usual brand of combustible cigarettes to the…
- Trial name
- NCT04019626
- Testing
- Continue-smoking, myblu Tobacco 2.5%, myblu Tobacco 4.0%
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Fontem Ventures BV
Smoking Cessation
Safety and Pharmacodynamcis of SELA-070 Nicotine Vaccine in Smokers
The purpose of this study is to evaluate the safety and pharmacodynamics of SELA-070. Increasing subcutaneous doses of SELA-070 will be administered to healthy smoker volunteers.
- Trial name
- NCT03148925
- Testing
- SELA-070, Saline
- Where
- Belgium
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Selecta Biosciences, Inc.
Tobacco Use Disorder, Smoking
A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers
Study to determine the safety and effectiveness of silver salt in Ariva® Silver Wintergreen Lozenge on discouraging smoking, by its imparting an unfavorable taste to the smoker when tobacco is smoked.
- Trial name
- NCT01337817
- Testing
- Ariva Silver Wintergreen, Ariva Wintergreen
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Star Scientific, Inc